Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah M Dry

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Oncotarget|December 29, 2016
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drugTakashi Murakami, Kentaro Igarashi, Kei Kawaguchi, et al.
Biochemical and Biophysical Research Communications|February 27, 2018
Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse modelsKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Journal of Cellular Biochemistry|May 9, 2018
Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapyKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
JCO Precision Oncology|January 8, 2019
Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical TrialTara A Russell, Mark A Eckardt, Takashi Murakami, et al.
Oncotarget|March 1, 2018
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse modelKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cell Cycle (Georgetown, Tex.)|March 16, 2017
The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years agoTakashi Murakami, Tasuku Kiyuna, Kei Kawaguchi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
American Journal of Clinical Oncology|April 18, 2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue SarcomasJoseph Daniel Pennington, Fritz C Eilber, Frederick R Eilber, et al.
Annals of Surgical Oncology|December 29, 2022
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal LiposarcomaMark A Eckardt, Danielle S Graham, Kyle D Klingbeil, et al.
Oncotarget|December 22, 2017
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapyKentaro Miyake, Takashi Murakami, Tasuku Kiyuna, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Oncotarget|December 29, 2016
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drugTakashi Murakami, Kentaro Igarashi, Kei Kawaguchi, et al.
Biochemical and Biophysical Research Communications|February 27, 2018
Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse modelsKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Journal of Cellular Biochemistry|May 9, 2018
Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapyKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
JCO Precision Oncology|January 8, 2019
Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical TrialTara A Russell, Mark A Eckardt, Takashi Murakami, et al.
Oncotarget|March 1, 2018
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse modelKentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cell Cycle (Georgetown, Tex.)|March 16, 2017
The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years agoTakashi Murakami, Tasuku Kiyuna, Kei Kawaguchi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse modelTakashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
American Journal of Clinical Oncology|April 18, 2018
Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue SarcomasJoseph Daniel Pennington, Fritz C Eilber, Frederick R Eilber, et al.
Annals of Surgical Oncology|December 29, 2022
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal LiposarcomaMark A Eckardt, Danielle S Graham, Kyle D Klingbeil, et al.
Oncotarget|December 22, 2017
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapyKentaro Miyake, Takashi Murakami, Tasuku Kiyuna, et al.
Pageof 15